cg-200745

Small moleculeexperimental

Clinical trial activity

6 trials · 7 clinical orgs · 0 marketing orgs

Phase 1
6
Phase 2
3
Phase 3
0
Phase 4
0

Earliest trial started Sep 1, 2010 (NCT01226407)

Timeline

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CN(C)CCCNC(=O)/C(=C/CCCCC(=O)NO)COc1cccc2ccccc12
Mol. weight
427.55 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • cg200745
  • cg200745
  • cg200745
  • cg-200745
  • n1-(3-(dimethylamino)propyl)-n8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05716919Phase 1Mar 9, 2023Machaon Biotherapeutics
NCT05249101Phase 1/Phase 2 (Phase 2)Jul 1, 2022CG Pharmaceuticals, Inc, University of California, San Francisco
NCT05345912Phase 1Dec 16, 2019CrystalGenomics, Inc., Seoul National University
NCT02737462Phase 1/Phase 2 (Phase 2)Jun 1, 2016CrystalGenomics, Inc., University of Ulsan
NCT02737228Phase 1/Phase 2 (Phase 2)Mar 1, 2016CrystalGenomics, Inc., Yonsei University
NCT01226407Phase 1Sep 1, 2010CrystalGenomics, Inc., University of Ulsan
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
CrystalGenomics, Inc.For profit4422010
University of UlsanAcademic/Hospital2022010
CG Pharmaceuticals, IncFor profit1112022
Machaon BiotherapeuticsFor profit1112023
Seoul National UniversityAcademic/Hospital1012019
University of California, San FranciscoAcademic/Hospital1012022
Yonsei UniversityAcademic/Hospital1012016
7 organizations
Page 1 / 1